J 2022

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

MOHAMED, Lounis, Rais Mohammed AMIR, Bencherit DJIHAD, Aouissi Hani AMIR, Oudjedi ADDA et. al.

Základní údaje

Originální název

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

Autoři

MOHAMED, Lounis, Rais Mohammed AMIR, Bencherit DJIHAD, Aouissi Hani AMIR, Oudjedi ADDA, Jitka KLUGAROVÁ (203 Česká republika, domácí), Andrea POKORNÁ (203 Česká republika, domácí), Miloslav KLUGAR (203 Česká republika, domácí) a Abanoub RIAD (818 Egypt, garant, domácí)

Vydání

Frontiers in Public Health, LAUSANNE, FRONTIERS MEDIA SA, 2022, 2296-2565

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30304 Public and environmental health

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.200

Kód RIV

RIV/00216224:14110/22:00125821

Organizační jednotka

Lékařská fakulta

UT WoS

000803613500001

Klíčová slova anglicky

adenoviral-based vaccine; COVID-19; health workers; inactivated virus vaccine; side effects

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 5. 4. 2023 08:16, Mgr. Tereza Miškechová

Anotace

V originále

Healthcare workers were prioritized in vaccination campaigns globally because they are exposed to the highest risk of contamination by SARS-CoV-2. This study evaluated the self-reported post-vaccination side effects of inactivated (BBIBP-CorV and CoronaVac) and adenoviral vector-based (AZD1222, Gam-COVID-Vac and Ad26.COV2.S) vaccines among Algerian healthcare workers using a validated questionnaire. The final analysis included 721 healthcare workers, with a predominance of females (59.1%) and younger individuals 20–30 years old (39.4%). Less than half (49.1%) of the respondents reported at least one local side effect, while 53.8% reported at least one systemic side effect. These side effects were more prevalent among viral vector vaccinees than inactivated virus vaccinees. The most common local side effects were injection site pain (39%) and arm pain (25.4%), while fatigue (34.4%), fever (28.4%), headache (24.8%) and myalgia (22.7%) were the most prevalent systemic side effects. The side effects appeared earlier among inactivated virus vaccines recipients and generally lasted for 2 to 3 days for the two vaccinated groups. The risk factors associated with a higher prevalence of side effects included female gender, allergic individuals, individuals with regular medication, those who contracted the COVID-19 disease and those who received two doses for both inactivated and viral-based vaccines groups. Despite the higher prevalence of post-vaccination side effects among adenoviral vector vaccines recipients, both vaccines groups were equally effective in preventing symptomatic infections, and no life-threatening side effects were reported in either vaccine group.

Návaznosti

EF19_073/0016943, projekt VaV
Název: Interní grantová agentura Masarykovy univerzity
LTC20031, projekt VaV
Název: Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Towards an International Network for Evidence-based Research in Clinical Health Research in the Czech Republic, INTER-COST
MUNI/A/1402/2021, interní kód MU
Název: Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu IV
Investor: Masarykova univerzita, Prohlubování znalostí v oblasti zdravotních rizik a benefitů výživy, prostředí a životního stylu IV
MUNI/IGA/1104/2021, interní kód MU
Název: COVID-19 Vaccines Safety Tracking in the Czech Republic (Akronym: CoVaST-CZ)
Investor: Masarykova univerzita, COVID-19 Vaccines Safety Tracking in the Czech Republic